MRK.DE - MERCK Kommanditgesellschaft auf Aktien

XETRA - XETRA Delayed Price. Currency in EUR
96.20
+0.20 (+0.21%)
At close: 5:35PM CET
Stock chart is not supported by your current browser
Previous Close96.00
Open95.96
Bid0.00 x 6700
Ask0.00 x 11200
Day's Range95.46 - 96.50
52 Week Range74.54 - 100.20
Volume387,634
Avg. Volume460,306
Market Cap41.688B
Beta (3Y Monthly)0.30
PE Ratio (TTM)21.63
EPS (TTM)4.45
Earnings DateMar 7, 2019
Forward Dividend & Yield1.25 (1.29%)
Ex-Dividend Date2018-04-30
1y Target EstN/A
  • Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine
    PR Newswire6 days ago

    Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

    Not intended for UK-based media DARMSTADT, Germany and NEW YORK , Feb. 16, 2019 /PRNewswire/ -- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 ...

  • Thomson Reuters StreetEvents15 days ago

    Edited Transcript of MRK.DE earnings conference call or presentation 14-Nov-18 1:00pm GMT

    Q3 2018 Merck KGaA Earnings Call

  • GlaxoSmithKline plc (GSK) Q4 2018 Earnings Conference Call Transcript
    Motley Fool16 days ago

    GlaxoSmithKline plc (GSK) Q4 2018 Earnings Conference Call Transcript

    GSK earnings call for the period ending December 31, 2018.

  • GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy
    Reuters17 days ago

    GSK pays up to $4.2 billion for Merck KGaA cancer immunotherapy

    GlaxoSmithKline bolstered its cancer drug development pipeline on Tuesday, agreeing to pay up to 3.7 billion euros ($4.2 billion) to Germany's Merck KGaA for the rights to a next-generation immunotherapy. Merck will receive an upfront payment of 300 million euros for the drug - known as M7824, or bintrafusp alfa - and is eligible for potential payments of up to 500 million euros depending on development milestones in lung cancer, the two companies said in statements on Tuesday. Merck could also get up to a further 2.9 billion euros, depending on commercial milestones, for a total deal value of as much as 3.7 billion euros.

  • PR Newswire29 days ago

    Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors

    DARMSTADT, Germany , January 24, 2019 /PRNewswire/ -- Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease ...

  • Reuterslast month

    BRIEF-Merck KGaA, Tencent Announce Collaboration On Digital Health Services In China

    Jan 23 (Reuters) - Merck Kgaa: * MERCK AND TENCENT ANNOUNCE COLLABORATION ON INTELLIGENT DIGITAL HEALTHCARE SERVICES IN CHINA * COLLABORATION WILL PRIMARILY FOCUS ON INCREASING PUBLIC DISEASE AWARENESS ...

  • Reuterslast month

    European nations weigh impact of Brexit on drug supplies

    FRANKFURT/DUBLIN, Jan 15 (Reuters) - Germany's drug safety regulator has concluded that Brexit will not put its patients at risk of losing access to essential drugs, while Ireland has drawn up a list of 24 medicines whose supply would be most vulnerable if Britain fails to conclude a divorce deal. Irish Prime Minister Leo Varadkar said a working group of health officials meeting weekly for the last two years had drawn up the watch list, but advised against stockpiling. "It is a really important message that I want to deliver to people in Ireland today, both to patients and pharmacists, that there is no need to stockpile medicines," Health Minister Simon Harris said at a news conference, warning that such action could inadvertently disturb the supply chain.

  • Reuters2 months ago

    Merck KGaA-Pfizer to end late-stage ovarian cancer treatment study

    Merck KGaA and Pfizer Inc said on Friday they were ending a late-stage study for their drug to treat a form of ovarian cancer in previously untreated patients. The results showed the drug, Bavencio, in combination with, or as a follow-on treatment to, platinum-based chemotherapy could not achieve the primary goal of progression-fee survival in patients. Last year, Bavencio, or avelumab, failed to prolong lives in a separate trial to evaluate the immunotherapy in gastric cancer patients.

  • PR Newswire2 months ago

    Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

    DARMSTADT, Germany , and NEW YORK , December 21, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced that data from a planned ...

  • PR Newswire2 months ago

    Merck KGaA, Darmstadt, Germany, Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon

    DARMSTADT, Germany , December 20, 2018 /PRNewswire/ -- Not intended for UK-based media   Agreement enables Merck KGaA, Darmstadt, Germany , to maintain an investment in the rapidly advancing oncology field ...

  • What Kind Of Shareholder Appears On The MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) Shareholder Register?
    Simply Wall St.2 months ago

    What Kind Of Shareholder Appears On The MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) Shareholder Register?

    The big shareholder groups in MERCK Kommanditgesellschaft auf Aktien (FRA:MRK) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to Read More...

  • PR Newswire2 months ago

    Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, which operates its healthcare business in the U.S. and Canada as EMD Serono, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to M7824, the first regulatory designation for the bifunctional immunotherapy, for the treatment of biliary tract cancer (BTC). The FDA orphan drug designation follows the recent presentation of the first clinical data for M7824 in BTC at the European Society of Medical Oncology (ESMO) congress in October.

  • PR Newswire3 months ago

    Merck KGaA, Darmstadt, Germany, in Agreement with Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it has entered into a licensing agreement with Cyclica Inc. for the use of Ligand Express®, a cloud-based in silico proteome screening platform. Ligand Express® is a structure-based and artificial intelligence (AI) augmented proteome screening platform that is being used to uncover novel targets that are modelled to interact with a small molecule.

  • Merck KGaA Partners With Startup for Image Tagging Software
    Bloomberg3 months ago

    Merck KGaA Partners With Startup for Image Tagging Software

    “In health care alone, there are massive amounts of unstructured data generated every day in labs,” Michael Vande Vrede, head of digital products at Merck KGaA, said Tuesday at the conference on Neural Information Processing Systems (NeurIPS) in Montreal, where the two companies announced their collaboration. V7 has created software called Graphotate that makes it easier and faster to annotate scientific imagers and videos.

  • Reuters3 months ago

    Big pharma leaves big gaps: drugmakers urged to do more for poor

    Many of the world's top drugmakers are not doing enough to provide medicines to poor countries, leaving big gaps in access to treatments in crucial disease areas, including cancer, according to a new report on Tuesday. The non-profit Access to Medicine Foundation (AMF) found companies overall were doing more than in the past to reach under-served populations, for example by setting lower prices for some drugs and improving transparency surrounding patents. What is more, research into urgently needed medicines for the developing world now relies on just a handful of companies, creating a fragile ecosystem where cutbacks by one player could have a significant impact on future supplies.

  • Reuters3 months ago

    UPDATE 1-Palantir to offer cancer analytics under JV deal with Germany's Merck

    Palantir Technologies Inc will set up a cancer data analytics joint venture with German lab supplies company Merck KGaA, as the U.S. analytics and security firm makes further inroads into health care. The new U.S.-based venture, called Syntropy, will offer cancer data analytics tools to research centres, combining Palantir's Foundry data platform with the customer knowledge of Merck's Life Science business, known as MilliporeSigma in North America, the companies said in a statement on Monday.

  • PR Newswire3 months ago

    Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

    DARMSTADT, Germany and NEW YORK , November 19, 2018 /PRNewswire/ -- Not intended for UK-based media     Merck KGaA, Darmstadt, Germany , and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN ...

  • Taking A Look At MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) ROE
    Simply Wall St.3 months ago

    Taking A Look At MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) ROE

    One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use Return Read More...

  • Simply Wall St.4 months ago

    How Should Investors React To MERCK Kommanditgesellschaft auf Aktien’s (FRA:MRK) CEO Pay?

    In 2016 Stefan Oschmann was appointed CEO of MERCK Kommanditgesellschaft auf Aktien (FRA:MRK). This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big Read More...

  • Reuters4 months ago

    Merck KGaA says might strike partnership deal this year

    German drugmaker Merck KGaA might agree partnership deals to jointly develop two of its most promising experimental medicines with a rival as early as this year, but more likely in 2019, its drug research and development chief said on Sunday. "It's possible even as early as the end of the year but that's really a stretch - or sometime in 2019," Luciano Rossetti told Reuters at the annual congress of the European Society for Medical Oncology in Munich on Sunday. Merck has a promising drug pipeline for the first time in several years but a decline in operating profit at its high-tech chemicals division has forced it to look into new ways to finance pharmaceutical development.

  • PR Newswire4 months ago

    Up to 10-Years of Follow-up Data Reaffirm Safety Profile of Investigational Cladribine Tablets

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the presentation of new data for cladribine tablets at the 34th Congress of the European Committee for Treatment and Research In Multiple Sclerosis (ECTRIMS) in Berlin, Germany. The data presented at ECTRIMS 2018 build on the existing real-world and clinical evidence around the safety and efficacy of cladribine tablets and reaffirm the benefit-risk profile of the oral treatment which is taken for a maximum of 20 days over two years.

  • PR Newswire5 months ago

    Merck KGaA, Darmstadt, Germany Data at ESMO 2018 Congress Highlight Multiple Therapeutics with Potential to Transform Cancer Care

    Not intended for distribution in the U.K. ESMO Abstract # Avelumab:  LBA6_PR, 659P, 1290P, 1291P, 1282P, 877P;  M7824 (TGF β-trap/anti-PD-L1):  1048O, 1463P, 1931P, 757P, 643P, 642P, 661P;  tepotinib (MET ...